Cancer Letters
Volume 225, Issue 1 , Pages 35-40 , 8 July 2005

Growth of LNCaP cells in monoculture and coculture with osteoblasts and response to tNOX inhibitors

  • Linara Axanova

      Affiliations

    • Department of Foods and Nutrition, Purdue University, 700 W. State Street, West Lafayette, IN 47907-205, USA
    • ,
  • D. James Morré

      Affiliations

    • Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 201 S. University Street, West Lafayette, IN 47907-2064, USA
    • ,
  • Dorothy M. Morré

      Affiliations

    • Department of Foods and Nutrition, Purdue University, 700 W. State Street, West Lafayette, IN 47907-205, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 765 494 8233; fax: +1 765 494 0906.

Received 19 August 2004 ,Revised 12 October 2004 ,Accepted 1 November 2004.

References 

  1. Rubin MA, Putzi M, Mucci N, Smith DC, Wojno K, Korenchuk S, et al. Rapid (“warm”) autopsy study for procurement of metastatic prostate cancer. Clin. Cancer Res. 2000;6:1038–1045
  2. Scher HI, Chung LW. Bone metastases: improving the therapeutic index. Semin. Oncol. 1994;21:630–656
  3. Morré DJ, Morré DM. Cell surface NADH oxidases (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative disease. Free Radical Res. 2003;37:795–808
  4. Morré DJ. NADH oxidase: a multifunctional ectoprotein of the eukaryotic cell surface. In:  Asard H,  Bérczi A,  Caubergs RJ editor. Plasma Membrane Redox Systems and Their Role in Biological Stress and Disease. Dordrecht: Kluwer; 1998;p. 121–156
  5. Bruno M, Brightman AO, Lawrence J, Werderitsh D, Morré DM, Morré DJ. Stimulation of NADH oxidase activity from rat liver plasma membranes by growth factors and hormones is decreased or absent with hepatoma plasma membranes. Biochem. J. 1992;284:625–628
  6. del Castillo-Olivares A, Yantiri F, Chueh P-J, Wang S, Sweeting M, Sedlak D, et al. A drug-responsive and protease-resistant peripheral NADH oxidase complex from the surface of HeLa S cells. Arch. Biochem. Biophys. 1998;358:125–140
  7. Morré DJ, Reust T. A circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea (N-4-methylphenylsulfonyl)-N′-(4-chlorophenyl)urea (LY181984) specific to sera from cancer patients. J. Bioenerg. Biomembr. 1997;29:281–289
  8. Morré DJ, Caldwell S, Mayorga A, Wu L-Y, Morré DM. NADH oxides activity from sera altered by capsaicin is widely distributed among cancer patients. Arch. Biochem. Biophys. 1997;342:224–230
  9. Chueh P-J, Kim C, Cho N, Morré DM, Morré DJ. Molecular cloning and characterization of a tumor-associated, growth-related, and time-keeping hydroquinone (NADH) oxidase (tNOX) of the HeLa cell surface. Biochemistry. 2002;41:3732–3741
  10. Morré DJ, Bridge A, Wu L-Y, Morré DM. Preferential inhibition by (−)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture. Biochem. Pharmacol. 2000;60:937–946
  11. Morré DJ, Chueh P-J, Morré DM. Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. Proc. Natl Acad. Sci. USA. 1995;92:1831–1835
  12. Morré DJ, Morré DM. Synergistic Capsicum-tea mixtures with anticancer activity. J. Pharm. Pharmacol. 2003;55:987–994
  13. Lee HL, Pienta KJ, Kim WJ, Cooper CR. The effect of bone-associated growth factors and cytokines on the growth of prostate cancer cells derived from soft tissue versus bone metastases in vitro. Int. J. Oncol. 2003;22:921–926
  14. Obasaju C, Hudes GR. Paclitaxel and docetaxel in prostate cancer. Hematol. Oncol. Clin. North Am. 2001;15:525–545
  15. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol. Rep. 2004;11:559–595
  16. Morré DJ, Morré DM, Sun H, Cooper R, Chang J, Janle EM. Tea catechin synergies in inhibition of cancer cell proliferation and of a cancer specific cell surface oxidase (ECTO-NOX). Pharmacol. Toxicol. 2003;92:234–241
  17. Roodman GD. Mechanisms of bone metastases. N. Eng. J. Med. 2004;350:1655–1664
  18. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res. 1993;473–480
  19. Pinski J, Parikh A, Bova GS, Isaacs JT. Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res. 2001;6372–6376

PII: S0304-3835(04)00877-8

doi: 10.1016/j.canlet.2004.11.017

Cancer Letters
Volume 225, Issue 1 , Pages 35-40 , 8 July 2005

Article Tools

* Image Usage & Resolution